Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Pfizer to be Dominant Biosimilar Developer Post Hospira Deal

Wednesday, April 8, 2015   (0 Comments)
Share |
From Biopharama-Reporter
By Dan Stanton

Pfizer will outpace the pack in terms of biosimilars in development once the $17bn acquisition of Hospira goes through.

[Read full article online]

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal